Sionna Therapeutics, Inc. SION
We take great care to ensure that the data presented and summarized in this overview for Sionna Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in SION
Top Purchases
Top Sells
About SION
Insider Transactions at SION
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2025
|
Elena Ridloff CFO & Head of Corp. Dev. |
SELL
Open market or private sale
|
Direct |
17,500
-19.66%
|
$385,000
$22.69 P/Share
|
|
Aug 20
2025
|
Michael Cloonan President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-4.37%
|
$550,000
$22.75 P/Share
|
|
Aug 20
2025
|
Michael Cloonan President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+4.19%
|
$150,000
$6.11 P/Share
|
|
Aug 19
2025
|
Elena Ridloff CFO & Head of Corp. Dev. |
SELL
Open market or private sale
|
Direct |
34,500
-27.93%
|
$724,500
$21.08 P/Share
|
|
Jun 27
2025
|
Tpg Gp A, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
60,000
+0.88%
|
$900,000
$15.84 P/Share
|
|
Feb 10
2025
|
Tpg Gp A, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,125,000
+14.4%
|
$20,250,000
$18.0 P/Share
|
|
Feb 10
2025
|
Tpg Gp A, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,875,547
+46.72%
|
-
|
|
Feb 10
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,125,000
+8.54%
|
$20,250,000
$18.0 P/Share
|
|
Feb 10
2025
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
7,951,493
+42.29%
|
-
|
|
Feb 10
2025
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
550,000
+12.93%
|
$9,900,000
$18.0 P/Share
|
|
Feb 10
2025
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
3,154,959
+50.0%
|
-
|
|
Feb 10
2025
|
Atlas Venture Fund Xi, L.P. |
BUY
Open market or private purchase
|
Indirect |
60,000
+6.91%
|
$1,080,000
$18.0 P/Share
|
|
Feb 10
2025
|
Atlas Venture Fund Xi, L.P. |
BUY
Conversion of derivative security
|
Indirect |
747,727
+50.0%
|
-
|
|
Feb 10
2025
|
Atlas Venture Fund Xi, L.P. |
BUY
Conversion of derivative security
|
Direct |
2,886,293
+50.0%
|
-
|
|
Feb 10
2025
|
Bruce Booth Director |
BUY
Open market or private purchase
|
Indirect |
60,000
+6.91%
|
$1,080,000
$18.0 P/Share
|
|
Feb 10
2025
|
Bruce Booth Director |
BUY
Conversion of derivative security
|
Indirect |
3,634,020
+50.0%
|
-
|
|
Feb 10
2025
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
550,000
+12.93%
|
$9,900,000
$18.0 P/Share
|
|
Feb 10
2025
|
Peter A. Thompson Director |
BUY
Conversion of derivative security
|
Indirect |
3,154,959
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
30M
Shares
From
13
Insiders
| Conversion of derivative security | 26.4M shares |
|---|---|
| Open market or private purchase | 3.53M shares |
| Exercise of conversion of derivative security | 25K shares |
Sell / Disposition
77K
Shares
From
2
Insiders
| Open market or private sale | 77K shares |
|---|